153996-48-6

Basic information

• Product Name: 1-(-)-CARBOXYMENTHYL-2,3:4,5-DI-O-CYCLOHEXYLIDENE-D-MYO-INOSITOL
• Synonyms: 1-(-)-CARBOXYMENTHYL-2,3:4,5-DI-O-CYCLOHEXYLIDENE-D-MYO-INOSITOL
• CAS NO: 153996-48-6
• Molecular Formula: C₂₉H₄₆O₈
• Molecular Weight: 522.674
• Mol File: 153996-48-6.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(-)-CARBOXYMENTHYL-2,3:4,5-DI-O-CYCLOHEXYLIDENE-D-MYO-INOSITOL(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(-)-CARBOXYMENTHYL-2,3:4,5-DI-O-CYCLOHEXYLIDENE-D-MYO-INOSITOL(153996-48-6)
• EPA Substance Registry System: 1-(-)-CARBOXYMENTHYL-2,3:4,5-DI-O-CYCLOHEXYLIDENE-D-MYO-INOSITOL(153996-48-6)

Safety Data

• Hazardous Substances Data: 153996-48-6(Hazardous Substances Data)

Usage

General Description

1-(-)-CARBOXYMENTHYL-2,3:4,5-DI-O-CYCLOHEXYLIDENE-D-MYO-INOSITOL is a chemical compound that belongs to the family of cyclohexylidene inositols. It is also known as D-chiro-inositol, an important secondary messenger that plays a crucial role in insulin signaling and glucose metabolism. 1-(-)-CARBOXYMENTHYL-2,3:4,5-DI-O-CYCLOHEXYLIDENE-D-MYO-INOSITOL has been studied for its potential in the treatment of polycystic ovary syndrome and diabetes due to its ability to improve insulin sensitivity and regulate ovarian function. Additionally, it has shown antioxidant properties and potential applications in the treatment of diseases related to oxidative stress. Its unique chemical structure and biological activities make it an interesting compound for further research and potential therapeutic applications.

Upstream product

• 41545-19-1 (+)-1,2:5,6-di-O-cyclohexylidene-myo-inositol 
• 14602-86-9 (1R,2S,5R)-menthyl chloroformate 
• 108-94-1 cyclohexanone 
• 87-89-8 D-myo-inositol 
• 1122-84-5 1-ethoxycyclohexene 
• 139640-08-7 1-O-(-)-menthoxycarbonyl-myo-inositol 

Downstream Products

• 380366-30-3 6-O-allyl-2,3:4,5-di-O-cyclohexylidene-1-O-(1R)-menthyloxycarbonyl-D-myo-inositol 
• 153996-49-7 Carbonic acid (1R,2S,5R)-2-isopropyl-5-methyl-cyclohexyl ester (1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentakis-methoxymethoxy-cyclohexyl ester 
• 153996-50-0 1D-1-O-2,3,4,5,6-(pentakis)methoxymethylene-myo-inositol 
• 220734-77-0 (2-azido-3,6-di-O-benzyl-2-deoxy-α-D-glucopyranosyl)-(1->6)-2,3,4,5-tetra-O-benzyl-1-O-(4-methoxybenzyl)-D-myo-inositol 
• 380366-32-5 (2-azido-3-O-benzyl-4,6-di-O-benzylidene-2-deoxy-α-D-glucopyranosyl)-(1->6)-2,3,4,5-tetra-O-benzyl-1-O-(4-methoxybenzyl)-D-myo-inositol 
• 380366-31-4 (3,4,6-tri-O-acetyl-2-azido-2-deoxy-α-D-glucopyranosyl)-(1->6)-2,3,4,5-tetra-O-benzyl-1-O-(4-methoxybenzyl)-D-myo-inositol 
• 382141-07-3 6-O-allyl-1-O-(4-methoxybenzyl)-D-myo-inositol 
• 211869-78-2 6-O-allyl-1-O-(p-methoxybenzyl)-2,3:4,5-di-O-cyclohexylidene-myo-inositol 
• 154459-82-2 1-D-6-O-allyl-2,3,4,5-tetra-O-benzyl-1-O-(4-methoxybenzyl)-myo-inositol 
• 129261-63-8 (+)-1D-2,3,4,5-tetra-O-benzyl-1-O-(4-methoxybenzyl)-myo-inositol 
• 164070-40-0 C₄₁H₆₁N₃O₁₅ 
• 139640-08-7 1-O-(-)-menthoxycarbonyl-myo-inositol 

Relevant articles and documents

Attempted synthesis of type-A inositolphosphoglycan mediators - Synthesis of a pseudohexasaccharide precursor

A block synthesis approach to the inositol-containing pseudohexasaccharide 1 is presented. The myo-inositol building block 6 has been prepared using a key regioselective acylation through a boron-tin exchange reaction and the 2-azido-2-deoxy glycosyl donors 15 and 17 have been synthesized from D-glucosamine using a diazo transfer reaction. The anomeric position of the mono- and disaccharide building blocks has been temporarily protected as phenyl thioglycoside and this function was then converted into the different leaving groups to perform the glycosylation reactions. Both trichloroacetimidates and fluorides have been used as glycosyl donors for the construction of the different glycosidic linkages. The protected pseudohexasaccharides 44, 48-50, which are precursors of pseudohexasaccharide 1, have been efficiently prepared and fully characterized. Pseudohexasaccharide 1 contains the fundamental structural features which have been proposed for type A inositolphosphoglycans, which may be involved in the insulin-signaling process.